Citigroup Inc. restated their neutral rating on shares of Hikma Pharmaceuticals Plc (LON:HIK) in a research report sent to investors on Wednesday.

Several other analysts also recently commented on HIK. Jefferies Group cut their target price on Hikma Pharmaceuticals Plc from GBX 2,990 ($37.36) to GBX 2,500 ($31.23) and set a buy rating on the stock in a research note on Monday, September 12th. Barclays PLC reiterated an overweight rating and set a GBX 2,800 ($34.98) target price on shares of Hikma Pharmaceuticals Plc in a research note on Thursday, August 4th. HSBC cut their target price on Hikma Pharmaceuticals Plc from GBX 1,985 ($24.80) to GBX 1,800 ($22.49) and set a hold rating on the stock in a research note on Friday, November 11th. Numis Securities Ltd reiterated a hold rating and set a GBX 2,660 ($33.23) target price on shares of Hikma Pharmaceuticals Plc in a research note on Wednesday, August 24th. Finally, Morgan Stanley cut their target price on Hikma Pharmaceuticals Plc from GBX 2,700 ($33.73) to GBX 2,500 ($31.23) and set an equal weight rating on the stock in a research note on Friday, August 12th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The company presently has an average rating of Buy and an average price target of GBX 2,337.40 ($29.20).

Hikma Pharmaceuticals Plc (LON:HIK) traded down 3.98% during trading on Wednesday, reaching GBX 1664.00. The company had a trading volume of 907,788 shares. The firm’s market capitalization is GBX 3992.74 billion. The firm’s 50-day moving average price is GBX 1,880.03 and its 200 day moving average price is GBX 2,198.23. Hikma Pharmaceuticals Plc has a one year low of GBX 1,575.00 and a one year high of GBX 2,703.00.

In other news, insider Darwazah,Mazen bought 155,991 shares of Hikma Pharmaceuticals Plc stock in a transaction dated Tuesday, September 6th. The shares were purchased at an average cost of GBX 2,194 ($27.41) per share, with a total value of £3,422,442.54 ($4,275,915.22). Also, insider Said Darwazah bought 50,000 shares of Hikma Pharmaceuticals Plc stock in a transaction dated Monday, September 26th. The stock was purchased at an average cost of GBX 2,078 ($25.96) per share, for a total transaction of £1,039,000 ($1,298,100.95).

Hikma Pharmaceuticals Plc Company Profile

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe.

Receive News & Stock Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related stocks with our FREE daily email newsletter.